ArticleScientific reports2019
Inhibition of Candida albicans morphogenesis by chitinase from Lactobacillus rhamnosus GG.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 1 synthesis or guideline pooled it, 104 citations in OpenAlex.
- Supplementation of Probiotics in Pregnant Women Targeting Group B Streptococcus Colonization: A Systematic Review and Meta-Analysis.Nutrients · 2022Pooled it
- Antifungal Activity Assessment of Postbiotic Mediators Derived From Lactobacillus rhamnosus GG and Lactobacillus reuteri Against Candida albicans.MicrobiologyOpen · 2026Article
- Evaluation of the Antifungal Effect of Lacticaseibacillus rhamnosus GG against Oral candidiasis in Healthy Sprague-Dawley Rats.Journal, genetic engineering & biotechnology · 2026Article
- Antifungal effect ofIranian journal of microbiology · 2026Article
- Enhanced production of chitinase from Bacillus cereus V5331 and evaluation of anti-candidal potential of enzyme: central composite design approach.Antonie van Leeuwenhoek · 2026Article
- Article
- Pangenome-based design of strain-specific primers enables precise monitoring of bacteria in human microbiome intervention trials.Scientific reports · 2026Article
- Factors influencing gut microbial colonization: A host-microbe-environment interaction perspective.Current research in food science · 2026Review
- Commensal bacterial glycosylation at the interface of host-bacteria interactions.Gut microbes · 2025Review
- Effects of Short-Chain Fatty Acid Combinations Relevant to the Healthy and Dysbiotic Gut upon Candida albicans.Current microbiology · 2025Article
- Baicalein as a potent antifungal agent againstFrontiers in microbiology · 2025Article
- The Oral Microbiome: A Key Determinant of Oral Health.Advances in experimental medicine and biology · 2025Review
- The pathobiology of human fungal infections.Nature reviews. Microbiology · 2024Review
- Riboflavin for women's health and emerging microbiome strategies.NPJ biofilms and microbiomes · 2024Review
- Novel domain-structure-containing chitinases A and B of Bacillus velezensis produced by recombinant Escherichia coli cells: Synergism on chitin degradation and their potential in suppressing Candida albicans cell germination.Journal, genetic engineering & biotechnology · 2024Article
- Chitinase-functionalized UiO-66 framework nanoparticles active against multidrug-resistant Candida Auris.BMC microbiology · 2024Article
- Multifactorial inhibition of Candida albicans by combinations of lactobacilli and probiotic Saccharomyces cerevisiae CNCM I-3856.Scientific reports · 2024Article
- Molecular Mechanisms ofMicroorganisms · 2024Review
- Review
- Cross interaction between bacterial and fungal microbiota and their relevance to human health and disease: mechanistic pathways and prospective therapy.Bioscience of microbiota, food and health · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lactobacilli have been evaluated as probiotics against Candida infections in several clinical trials, but with variable results. Predicting and understanding the clinical efficacy of Lactobacillus strains is hampered by an overall lack of insights into their modes of action. In this study, we aimed to unravel molecular mechanisms underlying the inhibitory effects of lactobacilli on hyphal morphogenesis, which is a crucial step in C. albicans virulence. Based on a screening of different Lactobacillus strains, we found that the closely related taxa L. rhamnosus, L. casei and L. paracasei showed stronger activity against Candida hyphae formation compared to other Lactobacillus species tested. By exploring the activity of purified compounds and mutants of the model strain L. rhamnosus GG, the major peptidoglycan hydrolase Msp1, conserved in the three closely related taxa, was identified as a key effector molecule. We could show that this activity of Msp1 was due to its ability to break down chitin, the main polymer in the hyphal cell wall of C. albicans. This identification of a Lactobacillus-specific protein with chitinase activity having anti-hyphal activity will assist in better strain selection and improved application in future clinical trials for Lactobacillus-based Candida-management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.